Stephen Johnston, ESMO 2020 – The MonarchE trial and Abemaciclib in High-risk Early Breast Cancer
Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 September 2020.
Questions
- What are the unmet needs in the treatment of HR-positive, HER2-negative early breast cancer and what factors influence the likelihood of recurrence? (0:12)
- Could you tell us a little about the aims, design and findings of the MonarchE clinical trial? (1:15)
- What is the clinical significance of these findings and how are they likely to impact on future clinical practice? (2:45)
- What other agents that could be effectively combined with CDK4/6 inhibitors, beyond endocrine therapy? (4:09)
- What will be the next steps in the clinical development of abemaciclib in breast cancer therapy? (6:02)
Speaker Disclosures: Stephen Johnston has provided consultancy for Novartis, Pfizer, Eli Lilly, Puma Biotechnology; has received speaker honoraria from Eisai, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche; and has received research funding for his institution from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. The MonarchE trial was sponsored by Eli Lilly and Company.
Filmed in coverage of the Virtual 2020 ESMO Congress.
